Mr. Simon joined MPM’s San Francisco office as general partner in October 2001. Prior to joining MPM, Mr. Simon was CEO and founder of Collabra Pharma, Inc., a pharmaceutical development company. Mr. Simon held several business development positions in his eleven years at Genentech including, most recently, vice president, Business & Corporate Development. During his tenure, he completed over fifty deals including product out-licensing, strategic alliances, and product acquisitions. Signature deals include the in-licensing of Rituxan, and the strategic alliances with Xoma on Raptiva and Novartis/Tanox on Xolair.

Prior to Genentech, Mr. Simon held various marketing and sales positions with several biopharmaceutical companies, including Amersham and Xoma. He was formerly a Director of Genitope, InterMune and Sangstat, and is currently on the board of directors at ARYx Therapeutics, Barrier Therapeutics, Biovitrum AB, CoTherix, Inc., Neosil, Inc., QuatRx Pharmaceuticals, and Rigel Pharmaceuticals. He is also on the Advisory Council of the Gladstone Institute, a private not-for-profit research institute affiliated with the University of California San Francisco (UCSF).

Mr. Simon received a BS in Microbiology from the University of Maryland and an MBA in Marketing from Loyola College.